FY2022 FINANCIAL RESULTS
ENDED MARCH 31, 2023

from the beginning

FY2022 FINANCIAL RESULTS ENDED MARCH 31, 2023

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING INFORMATION

• TOWARD ACHIEVEMENT OF CSP2021

I FY2022 Consolidated Financial Results

• FY2022 FINANCIAL RESULTS: OVERVIEW

• FY2022 FINANCIAL RESULTS

• FY2022 FINANCIAL RESULTS: MAIN PRODUCTS

• FY2022 FINANCIAL RESULTS: COST ITEMS

II Initiatives for Sustainable Growth

• XTANDI & STRATEGIC PRODUCTS: KEY EVENTS IN FY2022

• ENZALUTAMIDE/XTANDI: LATEST STATUS

• PROGRESS IN FOCUS AREA APPROACH (1/2):CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• PROGRESS IN FOCUS AREA APPROACH (2/2):AT845 PRELIMINARY DATA FROM FORTIS STUDY

• PROGRESS IN Rx+ PROGRAM: SUMMARY OF FY2022

III FY2023 Forecasts and Key Expected Events

• FY2023 FORECAST: OVERVIEW

• FY2023 FORECAST

• FY2023 FORECAST: MAIN PRODUCTS

• FY2023 FORECAST: COST ITEMS

• XTANDI & STRATEGIC PRODUCTS: KEY EVENTS EXPECTED IN FY2023

• FOCUS AREA APPROACH:KEY EVENTS EXPECTED IN FY2023

• NEW R&D OPERATING MODEL

• TOWARD ACHIEVEMENT OF CSP2021

• UPCOMING EVENT

APPENDIX

• CHANGE EXCHANGE RATES USED FOR ELIMINATION OF UNREALIZED PROFIT ON INVENTORIES (PRO FORMA FIGURES)
  

• FY2022: REVENUE BY REGION

• FY2022: SALES OF MAIN PRODUCTS

• FY2022 ACTUAL: FX RATE

• FY2023 FORECAST: FX RATE & FX SENSITIVITY

• FY2023 FORECAST: XTANDI (REGION)

• FY2023 FORECAST: PADCEV (REGION)

• BALANCE SHEET & CASH FLOW HIGHLIGHTS

• CAPITAL ALLOCATION

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE

• XTANDI & STRATEGIC PRODUCTS: STATUS UPDATE

• ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV) (1/4): NECTIN-4 TARGETED ADC OVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV) (2/4): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV) (3/4): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV) (4/4): FUTURE OUTLOOK

• GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AT132(RESAMIRIGENE BILPARVOVEC):rAAV8-Des-hMTM1

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9